Seelos Therapeutics, Inc. (SEELQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Nov 3, 2025, 3:48 PM EST

Seelos Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Net Income
4.09-37.88-73.53-66.05-19.1-51.26
Depreciation & Amortization
0.060.060.05---
Other Amortization
---1.580.15-
Asset Writedown & Restructuring Costs
--1.35.640.193
Stock-Based Compensation
3.773.995.078.352.170.46
Other Operating Activities
-33.95-2.492.732.890.2221.63
Change in Accounts Payable
9.2512.781.93-0.191.09-1.42
Change in Other Net Operating Assets
3.51-0.360.85-1.21-5.648.29
Operating Cash Flow
-13.27-23.91-61.6-49-20.91-19.31
Operating Cash Flow Growth
------

Financing Activities

Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Long-Term Debt Issued
----0.15-
Long-Term Debt Repaid
--7.64-1.89-13.55--
Net Debt Issued (Repaid)
-5.54-7.64-1.89-13.550.15-
Issuance of Common Stock
13.2720.210.56125.6226.1713
Repurchase of Common Stock
--1.2----
Other Financing Activities
---0.27--16.52
Financing Cash Flow
7.7311.38-1.6112.0726.3129.52

Net Cash Flow

Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Net Cash Flow
-5.55-12.54-63.263.075.410.22

Free Cash Flow

Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Levered Free Cash Flow
-34.28-5.11-35.6-30.29-16.29-9.26
Unlevered Free Cash Flow
-34.21-5.07-35.59-30.87-16.33-9.25

Additional Metrics

Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Cash Interest Paid
0.410.510.010.010.010.02
Change in Working Capital
12.7612.422.78-1.41-4.556.86